

Certificate of Analysis

GCN2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-934, 14-934-K, 14-934M

Parent Lot # WAD0197

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged, recombinant, human GCN2 full length, expressed by baculovirus in Sf21 insect cells. Purified using glutathione sepharose.

Purity 91% by SDS-PAGE and Coomassie blue staining. MW = 215kDa.

Specific Activity (Parent lot# WAD0197):

83U/mg, where one unit of GCN2, active activity is defined as 1nmol phosphate incorporated into 300μM (RSRSRSRSRSRSRSR) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 1.09mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 8–182ng of this lot of enzyme phosphorylated 300μM (RSRSRSRSRSRSRSR) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as GCN2 with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3μg of GCN2, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 100mM Tris/HCl pH8.5, 1mM EDTA.
2. **(RSRSRSRSRSRSRSR):** Use at a final assay concentration of 300µM. Prepare a 3mM stock and add 2.5µl of stock per assay point.
3. **10% Tween 20(w/v):** Use at a final assay concentration of 0.1% (w/v). Use 0.25µl of a 10% stock solution per assay point.
4. **1M NaCl:** Use at a final assay concentration of 100mM. Use 2.5µl of a 1M stock solution per assay point.
5. **GCN2, active:** Dilute with 20mM Tris/HCl pH8.5, 0.2mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 8–182ng per assay point.
6. **[γ-³³P]ATP:** 2.5 x MgAc/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of 1M NaCl.
3. Add 0.25µl 10% Tween 20.
4. Add 2.5µl of **(RSRSRSRSRSRSRSR)**.
5. Add 2.25µl of dH₂O.
6. Add **2.5µl (8–182ng) GCN2, active**.
7. Add 10µl of diluted [γ-³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

GCN2 Sequence Information

<u>Protein</u>	human GCN2
<u>Tags</u>	N-terminal GST
<u>Native sequence</u>	M237 of the recombinant protein is equivalent to M1 of human GCN2
<u>Accession number</u>	GenPept NP_001013725 The recombinant protein contains the amino acid substitution E556G with reference to GenPept NP_001013725. E556G is reported in GenPept CAH10626.

Recombinant GCN2 amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRLL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMA  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121 DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181 KRIEAIPIQID  KYLKSSKYIA  WPLQGWQATF  GGGDHPPKSD  LEVLFQGPEF  KGLRRRMAGG
241 RGAPGRGRDE  PPESYPQRQD  HELQALEAIY  GADFQDLRPD  ACGPVKEPPE  INLVLYPQGL
301 TGEEVYVKVD  LRVKCPPTYP  DVVPEIELKN  AKGLSNESVN  LLKSRLEELA  KKHCGEVMIF
361 ELAYHVQSFL  SEHNKPPPKS  FHEEMLERRA  QEEQQRLLEA  KRKEEQEQRE  ILHEIQRRKE
421 EIKEEKKRKE  MAKQERLEIA  SLSNQDHTSK  KDPGGHRTAA  ILHGGSPDFV  GNGKHRANSS
481 GRSRRERQYS  VCNSEDSPGS  CEILYFNMGS  PDQLMVHKGK  CIGSDEQLGK  LVYNALETAT
541 GGFVLLYEW  LQWQKKMGPF  LTSQEKEKID  KCKKQIQGTE  TEFNSLVKLS  HPNVVRYLAM
601 NLKEQDDSI  VDILVEHISG  VSLAAHLSHS  GPIPVHQLRR  YTAQLLSGLD  YLHSNSVVHK
661 VLSASNVLVD  AEGTVKITDY  SISKRLADIC  KEDVFEQTRV  RFSDNALPYK  TGKKGDVWRL
721 GLLLLLSLSQ  QECGEYPVTI  PSDLPADFQD  FLKKCVCLDD  KERWSPQQLL  KHSFINPQPK
781 MPLVEQSPED  SGGQDYVETV  IPSNRLPSAA  FFSETQRQFS  RYFIEFEELQ  LLGKGAFGAV
841 IKVQNKLDGC  CYAVKRIPIN  PASRQFRRIK  GEVTLLSRLH  HENIVRYYNA  WIERHERPAG
901 PGTPPPDSGP  LAKDDRAARG  QPASDTDGLD  SVEAAAPPPI  LSSSVEWSTS  GERSASARFP
961 ATGPGSSDDE  DDEDEHGGV  FSQSFLPASD  SESDIIFDNE  DENSKSQNQD  EDCNEKNGCH
1021 ESEPSVTTEA  VHYLYIQMEY  CEKSTLRDTI  DQGLYRDTVR  LWRLFREILD  GLAYIHEKGM
1081 IHRDLKPVNI  FLDSDDHVKI  GDFGLATDHL  AFSADSKQDD  QTGDLIKSDP  SGHLTGMVGT
1141 ALYVSPEVQG  STKSAYNQKV  DLFSLGIIFF  EMSYHPMVT  SERIFVLNQL  RDPTSPKFPE
1201 DFDDGEHAKQ  KSVISWLLNH  DPAKRPTATE  LLKSELLPPP  QMEESELHEV  LHHTLTNVDG
1261 KAYRTMMAQI  FSQRISPAID  YTYDSIDILK  NFSIRTAKMQ  QHVCETIIRI  FKRHGAVQLC
1321 TPLLLPRNRQ  IYEHNEAALF  MDHSGMLVML  PFDLRIPFAR  YVARNNILNL  KRYCIERVFR
1381 PRKLDRFHPK  ELLECAFDIV  TSTTNSFLPT  AEIIYTIYEI  IQEFPALQER  NYSIYLNHTM
1441 LLKAILLHCG  IPEDKLSQVY  IILYDAVTEK  LTRREVEAKF  CNLSLSSNSL  CRLYKFIEQK
1501 GDLQDLMPTI  NSLIKQKTGI  AQLVKYGLKD  LEEVVGLLKK  LGIKLQVLIN  LGLVYKVVQH
1561 NGIIFQFVAF  IKRRQRAVPE  ILAAGGRYDL  LIPQFRGPQA  LGPVPTAIGV  SIAIDKISAA
1621 VLNMEESVTI  SCDLLVSV  GQMSMSRAIN  LTQKLWTAGI  TAEIMYDWSQ  SQEELQEYCR
1681 HHEITYVALV  SDKEGSHVKV  KSFEKERQTE  KRVLETELVD  HVLQKLRTKV  TDERNGREAS
1741 DNLAVQNLKG  SFSNASGLFE  IHGATVVPIV  SVLAPEKLSA  STRRRYETQV  QTRLQTSAN
1801 LHQKSSEIEI  LAVDLPKETI  LQFLSLEWDA  DEQAFNTTVK  QLLSRLPKQR  YLKLVCDEIY
1861 NIKVEKKVSV  LFLYSYRDDY  YRILF

```

Recombinant GCN2 nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatatc  ttgaagaaaa  atatgaagag  catttgatg  agcgcatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatattgat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatagctt  atatagctga  caagcacaac

```

Certificate of Analysis

```

241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcgggttttg
301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagt
361 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa
421 acataatttaa atggtgatca tgtaacccat cctgacttca tgttgatga cgctcttgat
481 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat
661 ctggaagttc tgttccaggg gccgaattc aaaggcctac gtcgacgaat ggcaggtgga
721 agaggagccc caggtagagg aagagatgag cctcctgaat cctaccccca aaggcaagac
781 catgaattgc aggcactcga ggccatttac ggagccgact tccaggacct gcgccccgat
841 gcatgtggcc ccgtgaaaga gcccctgag atcaacctgg ttctgtatcc ccaaggactc
901 actggagaag aggtctacgt caaagtggat ttgagagtga aatgccacc tacatatcca
961 gacgttgtgc cagagatcga gttgaaaaat gccaaggac tgtctaataa aagcgtgaac
1021 ttgttgaagt cacgcctcga agaattggcc aagaaacatt gcggcgaggt catgatcttt
1081 gaactcgcac accacgtgca gagcttctcg agcagacaca acaaacctcc acccaagtca
1141 tttcacgaag aaatgctgga gcgcagagca caagaggagc agcagaggct gctggaggct
1201 aagcgcaaag aggaacaaga acaacgcgag atcctccacg agattcagcg cagaaaagag
1261 gaaatcaaag aagagaagaa gcgcaaggaa atggctaaac aagagcgctt ggaaattgct
1321 tctactagca accaggacca tacctccaaa aaggacctg gaggccatcg cacagctgcc
1381 atcctgcacg gtggctcacc cgacttcgtt ggaaatggta agcacagagc caatagctca
1441 ggccgctcaa ggagagaacg ccaatacagc gtgtgtaact ccgaggattc accaggtagc
1501 tgcgagatct tgtacttcaa tatgggttcc cccgatcagc tgatggtgca caaaggaaaa
1561 tgtatcggct ccgacgaaca attgggtaaa ttggtctata atgcattgga aaccgcaacc
1621 ggcggtttcg ttctcctgta tgaatgggtc ctgcagtggc agaaaaagat ggggtccctt
1681 ctcacctcac aagagaagga gaagattgat aagtgcaga aacagattca gggaaccgag
1741 acagagttta actctctcgt taagttgtcc caccctaatg tggtcagata cctggcaatg
1801 aatctcaagg agcaagacga ctccattgtt gtggatatcc tcgtggagca catctccgga
1861 gtcagcctcg ctgctcacct ctcacacagc ggcccaattc ctgtccacca actcagaagg
1921 tacacagctc aattgttgtc cgtcttgac tatttgact caaatagcgt ggtccacaag
1981 gtcctgtctg cctccaacgt gctcgttgat gccgagggca ccgtcaaat taccgattat
2041 agcatctcta aacgcctggc tgatatctgc aaggaggacg tgttcgaaca gactagggtc
2101 aggttttctg ataacgcatt gccatacaaa actggcaaaa aggggtgatgt ttggagactg
2161 ggcctgttgc tgttgtccct ctcaaaagg caagaatgcg gagaatatcc tgtgacaatt
2221 ccttcagacc tccccgctga tttccaggac tttctcaaaa agtgtgtctg cctggacgac
2281 aaggagaggt ggtcacccca acagctgctg aagcactcct tcatcaacc ccagcccaaa
2341 atgccccctg tggaacagtc ccctgaagat tctggcggcc aggactatgt tgaaacagtg
2401 atcccttcta atagactgcc ttctgtgca ttcttttctg aaacccaaag gcagttctct
2461 cgctacttta tcgagttcga agaactgcaa ctgctgggaa aaggtgcctt tggcgtgtc
2521 atcaaagtgc agaataagct cgacggttgc tgttacgctg tgaagagaat ccctattaac
2581 ccagctagca gacaattcag gagaatcaaa ggtgaggtca cttgtctctc tagattgcac
2641 cagagagaaca tcgtgagata ttacaacgca tggatcgaga ggcatgagag gcccgagggt
2701 ccaggcacac ctccccaga tagcggccca ctggctaagg atgaccgcgc tgcacgggc
2761 cagcgacccct ccgataccga tggcttgat tccgttgaag ctgctgcacc acccctatc
2821 ctctcctctt cagtggaaatg gtccactagc ggcgagcgtc cagcttcgc tcgcttcca
2881 gccactggac ctggatcttc agacgacgaa gacgacgatg aggatgagca cggcggagt
2941 tttagccagt ctttttgcc agccagcgac tctgagtcg atattatctt cgataatgag
3001 gacgagaata gcaaaagcca gaatcaggac gaggattgca acgaaaagaa cggatgtcat
3061 gagtcagagc catcagtgc cactgaagca gtgcactact tgtacatcca gatggagtat
3121 tgtgagaagt ctaccctcag agatactatt gatcaaggcc tgtataggga tactgtccgc
3181 ctgtggcgcc tcttcaggga gatcctggat ggactggctt acatccacga gaaggcatg
3241 atccatcgcg atctcaagcc cgtcaacatt tttctggatt cagacgatca cgtgaaaatc
3301 ggagatttcg gcctggccac cgacctctc gccttttcg ctgatagcaa acaagacgac
3361 cagaccggcg acctgattaa gtccgatcct agcggtcatt tgactggcat ggtcggcaca
3421 gccctgtacg tgagccctga agttcaaggt agcactaaat ctgcatacaa tcagaaagt
3481 gacttggtct ccctcgcat tttttctt gaaatgagct accatcctat ggtgacagcc
3541 agcgaacgca tttctgtgct gaatcagctc agggacccta catcaccaa gttccctgaa

```

Certificate of Analysis

```

3601 gacttcgacg atggagaaca cgctaagcaa aagtctgtga tctcctggct gttgaatcat
3661 gatcccgcca agcgcccaac tgctactgaa ttgctgaagt ctgaattgct cccaccacct
3721 cagatggaag aatccgaact ccacgaggtg ctccatcaca ctttgacaaa cgctgatggg
3781 aaggcttacc gcaactatgat ggacaaaatc ttttccaga ggatctcccc cgctattgac
3841 tacacctacg actcagatat tctcaagggt aatttctcca tcagaaccgc aaagatgcag
3901 cagcatgtgt gtgagacaat tattcgcatc tttaagcgcc acggcgctgt gcaactctgt
3961 actcctctct tgctgcctag aaaccgccag atctatgagc acaatgaggc agccctgttc
4021 atggaccatt ctggcatgct gggtatgtcg ccatttgacc tccgcattcc tttcgcccg
4081 tacgtcgccc gcaataacat cctgaatctg aaaagggtact gcatcgagcg cgtgttccgc
4141 cccagaaaac tggatagggt ccacccaaag gagttgctgg aatgtgcatt tgacatcgtt
4201 acatccacta caaacagctt tctccctacc gctgagatca tttataccat ttacgagatc
4261 atccaggagt tccccgccct gcaggagaga aattactcta tttatctcaa tcacactatg
4321 ttgttgaagg ccatcctgct gcattgcggc attcctgagg acaaactgtc ccaagtctac
4381 atcatcttgt acgacgtgtg gacagaaaag ctgaccagaa gggagggttg ggctaagttc
4441 tgaacctgtt ccctgtcttc taattctttg ttaggctgtg ataagtttat cgagcagaag
4501 ggcgacctcc aggatctcat gccaccatc aactctctga tcaagcagaa aaccggtatt
4561 gctcaactgg tcaagtacgg cctgaaggat ctggaggagg tggtcggact gctgaagaaa
4621 ctgggcatca agttgcaggt tttgatcaat ttgggcctgg tttataaggt gcagcagcat
4681 aacggcatta ttttccaatt cgtggctttt atcaagagac gccaacgcgc cgtgcctgag
4741 attctcgtcg ctggcggtag atatgatctg ctgatccac agtttcgcgg tccccaggca
4801 ctgggtcccc tgcccaccgc tatcgagtc agcatcgcca tcgataagat ctcagctgct
4861 gtgctgaaca tgggaagagag cgttaccatc agctcctgtg acctgctggt ggtttccgtg
4921 ggacaaatgt caatgtcaag agccatcaac ctactcaga agctgtggac cgcaggcatc
4981 acagctgaga tcatgtacga ttggtcacag agccaggagg aactccagga atactgtcgc
5041 caccacgaga ttacatatgt tgctctggtg tccgacaagg agggctcca cgtgaaagtg
5101 aaatccttcg aaaaggaaag acaaactgag aagcgcgtgc tggagactga actcgtggac
5161 cacgtcctgc agaaactccg cacaaaggtc accgatgaaa gaaacggtag agaggcttct
5221 gacaatctcg ctgttcagaa tctcaaaggc tcatttagca acgctagcgg tttgtttgag
5281 attcatggcg ccactgttgt gcctattgtc tcagtgtctg ctcctgaaaa gctgtcagct
5341 agcaccagac gcagatacga aacacagggt caaaccaggc tccagactag cctggctaac
5401 ctgcatcaaa agtcttctga aatcgagatt ctggccgtcg atctgccccaa agagacaatc
5461 ctgcaatttc tgtcactcga gtgggacgcc gacgagcagg cttttaacac taccgttaaa
5521 caattgtctgt cccgcctccc caaacagcgc tatctgaagc tgggtgtgcga tgaaatctac
5581 aacattaagg tggaaaagaa agtctctgtg ttgttcttgt actcatacag agatgactac
5641 tacagaatct tgttttag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services